➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Moodys
Boehringer Ingelheim
AstraZeneca
Mallinckrodt
Merck

Last Updated: September 25, 2020

DrugPatentWatch Database Preview

Claims for Patent: 9,365,645

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,365,645
Title:Methods for controlling the galactosylation profile of recombinantly-expressed proteins
Abstract: The present invention relates to methods for modulating the glycosylation profile of recombinantly-expressed proteins. In particular, the present invention relates to methods of controlling the galactosylation profile of recombinantly-expressed proteins by supplementing production medium, e.g., a hydrolysate-based or a chemically defined medium, with manganese and/or D-galactose.
Inventor(s): Bengea; Cornelia (Auburn, MA), Rives; Lisa M. (Natick, MA), Hossler; Patrick (Westborough, MA)
Assignee: AbbVie, Inc. (North Chicago, IL)
Application Number:15/014,694
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,365,645
Patent Claims:1. A composition comprising an antibody comprising the heavy and light chain variable domains of adalimumab, wherein less than 70% of the total N-linked oligosaccharides present on said antibody are of an agalactosyl fucosylated biantennary oligosaccharide form (sum NGA2F+NGA2F-GlcNAc).

2. The composition of claim 1, wherein the antibody is adalimumab.

3. The composition of claim 1, wherein 49-69% of the total N-linked oligosaccharides present on said antibody are of an agalactosyl fucosylated biantennary oligosaccharide form (sum NGA2F+NGA2F-GlcNAc).

4. The composition of claim 1, wherein 55-65% of the total N-linked oligosaccharides present on said antibody are of an agalactosyl fucosylated biantennary oligosaccharide form (sum NGA2F+NGA2F-GlcNAc).

5. The composition of claim 1, wherein 26-40% of the total N-linked oligosaccharides present on said antibody are of a galactose-containing fucosylated biantennary oligosaccharide form (sum of NA1F+NA2F).

6. The composition of claim 1, wherein 35-44% of the total N-linked oligosaccharides present on said antibody are of a galactose-containing fucosylated biantennary oligosaccharide form (sum of NA1F+NA2F).

7. The composition of claim 1, wherein 30-40% of the total N-linked oligosaccharides present on said antibody are of a galactose-containing fucosylated biantennary oligosaccharide form (sum of NA1F+NA2F).

8. The composition of claim 1, wherein said antibody has been produced by culturing a mammalian cell in a cell culture media which has been supplemented with a manganese supplement and a galactose supplement.

9. The composition of claim 8, wherein the cell culture media has been supplemented with 0.2-100 .mu.M of a manganese supplement and 1-100 mM of a galactose supplement.

10. The composition of claim 8, wherein the cell culture media comprises a hydrolysate based media or a chemically defined media.

11. The composition of claim 8, wherein the mammalian cell is a CHO cell or an NSO cell.

12. A pharmaceutical composition comprising the composition of claim 1 and a pharmaceutically acceptable carrier.

13. The pharmaceutical composition of claim 12, wherein the pharmaceutically acceptable carrier comprises a polyalcohol.

14. The pharmaceutical composition of claim 12, wherein the pharmaceutically acceptable carrier comprises mannitol, sodium chloride, sodium phosphate or polysorbate 80.

15. The pharmaceutical composition of claim 12, wherein the pharmaceutical composition is suitable for parenteral administration.

16. A composition comprising adalimumab, wherein less than 70% of the total N-linked oligosaccharides present on said adalimumab are of an agalactosyl fucosylated biantennary oligosaccharide form (sum NGA2F+NGA2F-GlcNAc).

17. The composition of claim 16, wherein 49-69% of the total N-linked oligosaccharides present on said adalimumab are of an agalactosyl fucosylated biantennary oligosaccharide form (sum NGA2F+NGA2F-GlcNAc).

18. The composition of claim 16, wherein 55-65% of the total N-linked oligosaccharides present on said adalimumab are of an agalactosyl fucosylated biantennary oligosaccharide form (sum NGA2F+NGA2F-GlcNAc).

19. The composition of claim 16, wherein 26-40% of the total N-linked oligosaccharides present on said adalimumab are of a galactose-containing fucosylated biantennary oligosaccharide form (sum of NA1F+NA2F).

20. The composition of claim 16, wherein 35-44% of the total N-linked oligosaccharides present on said adalimumab are of a galactose-containing fucosylated biantennary oligosaccharide form (sum of NA1F+NA2F).

21. The composition of claim 16, wherein 30-40% of the total N-linked oligosaccharides present on said adalimumab are of a galactose-containing fucosylated biantennary oligosaccharide form (sum of NA1F+NA2F).

22. The composition of claim 16, wherein said adalimumab has been produced by culturing a mammalian cell in a cell culture media which has been supplemented with a manganese supplement and a galactose supplement.

23. The composition of claim 22, wherein the cell culture media has been supplemented with 0.2-100 .mu.M of a manganese supplement and 1-100 mM of a galactose supplement.

24. The composition of claim 22, wherein the cell culture media comprises a hydrolysate based media or a chemically defined media.

25. The composition of claim 22, wherein the mammalian cell is a CHO cell or an NSO cell.

26. A pharmaceutical composition comprising the composition of claim 16 and a pharmaceutically acceptable carrier.

27. The pharmaceutical composition of claim 26, wherein the pharmaceutically acceptable carrier comprises a polyalcohol.

28. The pharmaceutical composition of claim 26, wherein the pharmaceutically acceptable carrier comprises mannitol, sodium chloride, sodium phosphate or polysorbate 80.

29. The pharmaceutical composition of claim 26, wherein the pharmaceutical composition further comprises polysorbate 80.

30. The pharmaceutical composition of claim 26, wherein the pharmaceutical composition is suitable for parenteral administration.

Details for Patent 9,365,645

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Abbvie Inc HUMIRA adalimumab SYRINGE 125057 001 2002-12-31   Start Trial AbbVie, Inc. (North Chicago, IL) 2031-04-27 RX search
Abbvie Inc HUMIRA adalimumab VIAL 125057 002 2002-12-31   Start Trial AbbVie, Inc. (North Chicago, IL) 2031-04-27 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
McKesson
Boehringer Ingelheim
Moodys
Merck
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.